1. Home
  2. IMCR vs CRTO Comparison

IMCR vs CRTO Comparison

Compare IMCR & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

N/A

Current Price

$33.78

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Logo Criteo S.A.

CRTO

Criteo S.A.

N/A

Current Price

$18.36

Market Cap

923.5M

ML Signal

N/A

Company Overview

Basic Information
Metric
IMCR
CRTO
Founded
2008
2005
Country
United Kingdom
France
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
923.5M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
IMCR
CRTO
Price
$33.78
$18.36
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$66.33
$34.00
AVG Volume (30 Days)
538.7K
382.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
30.39
38.95
EPS
0.23
0.37
Revenue
$249,428,000.00
$2,296,692,000.00
Revenue This Year
$14.57
N/A
Revenue Next Year
$8.21
$5.54
P/E Ratio
$147.83
$49.68
Revenue Growth
43.05
27.65
52 Week Low
$27.56
$15.58
52 Week High
$40.71
$25.29

Technical Indicators

Market Signals
Indicator
IMCR
CRTO
Relative Strength Index (RSI) 53.98 39.49
Support Level $30.74 $16.50
Resistance Level $33.89 $19.51
Average True Range (ATR) 1.37 0.94
MACD -0.18 -0.57
Stochastic Oscillator 43.26 28.10

Price Performance

Historical Comparison
IMCR
CRTO

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.

Share on Social Networks: